NEXS BioMedica

04/02/2025

Check out the new NEXS BioMedica- Horizons Commercial

02/26/2025

Thrilled to announce that our sister company, NEXS Technology, has been accepted into the AWS Startup Program. This achievement accelerates the development of CancerScope-AI—our advanced AI tool transforming cancer research and precision medicine. With AWS powering our efforts, we're one step closer to improving outcomes for cancer patients. Congratulations to the NEXS Technology Group team; we are proud to be on this journey together.

02/22/2025

NEXS BioMedica is proud to launch CancerScope-AI, a revolutionary AI tool with NEXS Technology Group. It’s bringing hope to rare cancer patients—smart tech for a tough fight. Check it out: https://www.nexsbiomedica.com

NEXS BioMedica Unveils CancerScope-AI: A Game-Changer in Rare Cancer Treatment. NEXS BioMedica, a forward-thinking biotech pharmaceutical company, proudly introduces CancerScope-AI, an innovative artificial intelligence system set to transform the battle against rare cancers. - PR13063247

02/22/2025

‘A Lifeline Preserved or a Mirage of Relief?’ It’s about a federal judge pausing NIH funding cuts that could’ve gutted research—including NEXS BioMedica’s work on Adrenocortical carcinoma, a rare killer. The Trump admin’s push could reshape biotech—will it spark innovation or choke it? Read the stakes for us and countless others fighting to save lives. Link in bio/comments!

February 21, 2025 — Today, a federal judge’s gavel struck a temporary blow against the Trump administration’s aggressive push to slash NIH…

02/21/2025

Big win for science today: a federal judge extended the block on NIH funding cuts, halting a 15% cap on indirect costs. For NEXS BioMedica, this means critical research stays funded—labs keep running, ideas keep growing. For the broader biomedical community, it’s a lifeline: no slashed budgets, no stalled trials, just a chance to keep pushing the boundaries of innovation. Resilience is paying off, but the fight’s not over—stay vigilant. Here’s to science thriving against the odds.

02/21/2025

February 21, 2025—In biopharma, the ground’s shaking: NIH funding’s on the chopping block (Washington Post), but the pulse of innovation beats stronger than ever—think AI breakthroughs and rare disease wins (GOV.UK, CBS). At NEXS BIOMEDICA, we’re not flinching. As CEO, I’m leading our charge against adrenocortical carcinoma—a rare killer with too little hope—blending biopharmaceutical grit with next-gen tech. Yesterday’s patent filing marks our latest strike, and we’re chasing an NIH SBIR to fuel it.

This isn’t just science—it’s a fight for patients stuck with outdated options. We’re crafting a future where ACC meets its match. Who’s with us to redefine healthcare’s tough corners? Drop your thoughts below. hashtag hashtag hashtag hashtag hashtag hashtag

02/20/2025

February 20, 2025—biotech’s facing headwinds, but at NEXS BIOMEDICA, we’re charging forward. With NIH budgets under fire (Washington Post) and AI breakthroughs lighting the way (GOV.UK), the moment to innovate is now. As Chairman, I’m steering us toward rare cancer solutions—advancing a drug candidate and harnessing AI to crack complex data. We filed a provisional patent today to lock in our latest leap, prepping for an NIH SBIR push by April 5. In a world of cuts and chaos (Reuters), we’re betting on precision and grit to transform rare cancer care. How do we keep this fight alive? Let’s talk.

02/18/2025

At NEXS BioMedica, we’re a leading biotech pharmaceutical company dedicated to advancing healthcare. With innovative research and development in areas like oncology, immunology, and beyond, our cutting-edge solutions are transforming patient care and redefining what’s possible in medicine.

Discover how our passion for precision science is creating breakthrough therapies and shaping the future of healthcare. Visit us at https://www.nexsbiomedica.com to learn more about our journey and innovations.

“We aren’t just imagining the future; we’re creating it.”

02/16/2025

From Blockbuster Ambitions to a Life-Saving Mission: How a Call from My Friend with ACC Changed My Course

My journey began with a singular focus—to create a blockbuster drug, a groundbreaking GLP-1 agonist that would revolutionize metabolic disease treatment. I was deeply immersed in developing an innovative delivery system that promised to set new standards in precision medicine.

12/23/2024

May your holidays sparkle with health and discovery—just like this festive, tree-shaped cell! From all of us at NEXS BioMedica, wishing you a joyful and innovative holiday season.

12/05/2024

💡 The True Cost of Inefficiency in Healthcare 💡

The U.S. healthcare system wastes up to $935 billion annually—a staggering number that represents missed opportunities to improve lives and outcomes.

Here’s where the waste occurs:
🔵 Administrative Complexity: $266B
🔵 Pricing Failures: $241B
🔵 Failures in Care Delivery: $166B

At NEXS BioMedica, we are committed to reducing this waste by developing innovative therapies for critical health challenges, including obesity, metabolic disorders, and cancer. Diseases like cancer, where time and precision matter most, demand a system that eliminates inefficiencies and accelerates access to life-changing treatments.

Our focus includes:
✔️ Precision Medicine: Developing therapies tailored to individual patient needs.
✔️ Health Equity: Advocating for accessible care for underserved populations.
✔️ Innovative Research: Addressing both systemic inefficiencies and pressing medical needs.

By tackling waste and advocating for smarter healthcare spending, we aim to channel resources toward improving lives and delivering the best possible outcomes for patients.

🔗 What changes do you think are most critical to building a more efficient and impactful healthcare system? Let’s start the conversation.

12/05/2024

Promising cures, bold advocacy, and a commitment to health equity—NEXS BioMedica is shaping the future of healthcare. Join us in transforming lives, one breakthrough at a time. 💡🌍

12/03/2024

🌟 Big News from NEXS BioMedica! 🌟
Obesity is a growing epidemic affecting millions, and we’re taking a stand. NEXS BioMedica is calling for reforms to fast-track innovative treatments and improve patient access to life changing therapies. It’s time to treat obesity like the chronic illness it is!

💡 Learn more about our mission and how we’re addressing this critical issue.

�🔗 Read the press release: https://www.prlog.org/13050844-nexs-biomedica-urges-policy-reforms-to-combat-obesity-with-accelerated-drug-development.html

Let’s innovate, collaborate, and transform healthcare together.